BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

363 related articles for article (PubMed ID: 19050681)

  • 1. Utility of tissue microarrays for profiling prognostic biomarkers in clinically localized prostate cancer: the expression of BCL-2, E-cadherin, Ki-67 and p53 as predictors of biochemical failure after radical prostatectomy with nested control for clinical and pathological risk factors.
    Nariculam J; Freeman A; Bott S; Munson P; Cable N; Brookman-Amissah N; Williamson M; Kirby RS; Masters J; Feneley M
    Asian J Androl; 2009 Jan; 11(1):109-18. PubMed ID: 19050681
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tumour growth fraction measured by immunohistochemical staining of Ki67 is an independent prognostic factor in preoperative prostate biopsies with small-volume or low-grade prostate cancer.
    Zellweger T; Günther S; Zlobec I; Savic S; Sauter G; Moch H; Mattarelli G; Eichenberger T; Curschellas E; Rüfenacht H; Bachmann A; Gasser TC; Mihatsch MJ; Bubendorf L
    Int J Cancer; 2009 May; 124(9):2116-23. PubMed ID: 19117060
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Preoperative p53, bcl-2, CD44 and E-cadherin immunohistochemistry as predictors of biochemical relapse after radical prostatectomy.
    Brewster SF; Oxley JD; Trivella M; Abbott CD; Gillatt DA
    J Urol; 1999 Apr; 161(4):1238-43. PubMed ID: 10081877
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Protein expression of p53, bcl-2, and KI-67 (MIB-1) as prognostic biomarkers in patients with surgically treated, clinically localized prostate cancer.
    Moul JW; Bettencourt MC; Sesterhenn IA; Mostofi FK; McLeod DG; Srivastava S; Bauer JJ
    Surgery; 1996 Aug; 120(2):159-66; discussion 166-7. PubMed ID: 8751578
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The role of p53, bcl-2 and E-cadherin expression in predicting biochemical relapse for organ confined prostate cancer in Taiwan.
    Wu TT; Hsu YS; Wang JS; Lee YH; Huang JK
    J Urol; 2003 Jul; 170(1):78-81. PubMed ID: 12796649
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Utility of Bcl-2, P53, Ki-67, and caveolin-1 immunostaining in the prediction of biochemical failure after radical prostatectomy in a Japanese population.
    Goto T; Nguyen BP; Nakano M; Ehara H; Yamamoto N; Deguchi T
    Urology; 2008 Jul; 72(1):167-71. PubMed ID: 18384856
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Angiogenesis, p53, bcl-2 and Ki-67 in the progression of prostate cancer after radical prostatectomy.
    Moul JW
    Eur Urol; 1999; 35(5-6):399-407. PubMed ID: 10325496
    [TBL] [Abstract][Full Text] [Related]  

  • 8. p53 and bcl-2 immunohistochemistry in preoperative biopsies as predictors of biochemical recurrence after radical prostatectomy.
    Oxley JD; Winkler MH; Parry K; Brewster S; Abbott C; Gillatt DA
    BJU Int; 2002 Jan; 89(1):27-32. PubMed ID: 11849156
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bcl-2 is significantly overexpressed in localized radio-recurrent prostate carcinoma, compared with localized radio-naive prostate carcinoma.
    Rosser CJ; Reyes AO; Vakar-Lopez F; Levy LB; Kuban DA; Hoover DC; Lee AK; Pisters LL
    Int J Radiat Oncol Biol Phys; 2003 May; 56(1):1-6. PubMed ID: 12694817
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic Factors of Prostate Cancer in Tunisian Men: Immunohistochemical Study.
    Missaoui N; Abdelkarim SB; Mokni M; Hmissa S
    Asian Pac J Cancer Prev; 2016; 17(5):2655. PubMed ID: 27268646
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The role of tumor biomarkers as predictors of serum PSA recurrence after radical prostatectomy.
    de la Taille A; Buttyan R; Benson MC; Katz AE
    Semin Urol Oncol; 1998 Aug; 16(3):137-44. PubMed ID: 9741418
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prediction of biochemical relapse for stage pT3 prostate cancer following radical prostatectomy.
    Wu TT; Wang JS; Lu CM; Lee YH; Huang JK
    Zhonghua Yi Xue Za Zhi (Taipei); 2000 Feb; 63(2):124-30. PubMed ID: 10677923
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An immunohistochemical signature comprising PTEN, MYC, and Ki67 predicts progression in prostate cancer patients receiving adjuvant docetaxel after prostatectomy.
    Antonarakis ES; Keizman D; Zhang Z; Gurel B; Lotan TL; Hicks JL; Fedor HL; Carducci MA; De Marzo AM; Eisenberger MA
    Cancer; 2012 Dec; 118(24):6063-71. PubMed ID: 22674438
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Apoptotic and predictive factors by Bax, Caspases 3/9, Bcl-2, p53 and Ki-67 in prostate cancer after 12 Gy single-dose.
    Pisani C; Ramella M; Boldorini R; Loi G; Billia M; Boccafoschi F; Volpe A; Krengli M
    Sci Rep; 2020 Apr; 10(1):7050. PubMed ID: 32341393
    [TBL] [Abstract][Full Text] [Related]  

  • 15. p27(kip1) and Ki-67 (MIB1) immunohistochemical expression in radical prostatectomy specimens of patients with clinically localized prostate cancer.
    Revelos K; Petraki C; Gregorakis A; Scorilas A; Papanastasiou P; Tenta R; Koutsilieris M
    In Vivo; 2005; 19(5):911-20. PubMed ID: 16097446
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Biostatistical modeling using traditional variables and genetic biomarkers for predicting the risk of prostate carcinoma recurrence after radical prostatectomy.
    Bauer JJ; Connelly RR; Sesterhenn IA; Bettencourt MC; McLeod DG; Srivastava S; Moul JW
    Cancer; 1997 Mar; 79(5):952-62. PubMed ID: 9041158
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Characterisation of biomolecular profiles in primary high-grade prostate cancer treated by radical prostatectomy.
    Augustin H; Hammerer PG; Graefen M; Palisaar J; Daghofer F; Huland H; Erbersdobler A
    J Cancer Res Clin Oncol; 2003 Nov; 129(11):662-8. PubMed ID: 14513368
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ki-67 in screen-detected, low-grade, low-stage prostate cancer, relation to prostate-specific antigen doubling time, Gleason score and prostate-specific antigen relapse after radical prostatectomy.
    Khatami A; Hugosson J; Wang W; Damber JE
    Scand J Urol Nephrol; 2009; 43(1):12-8. PubMed ID: 18949633
    [TBL] [Abstract][Full Text] [Related]  

  • 19. ERG immunohistochemistry is not predictive for PSA recurrence, local recurrence or overall survival after radical prostatectomy for prostate cancer.
    Hoogland AM; Jenster G; van Weerden WM; Trapman J; van der Kwast T; Roobol MJ; Schröder FH; Wildhagen MF; van Leenders GJ
    Mod Pathol; 2012 Mar; 25(3):471-9. PubMed ID: 22080055
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Early prostate-specific antigen relapse after radical retropubic prostatectomy: prediction on the basis of preoperative and postoperative tumor characteristics.
    Graefen M; Noldus J; Pichlmeier U; Haese A; Hammerer P; Fernandez S; Conrad S; Henke R; Huland E; Huland H
    Eur Urol; 1999; 36(1):21-30. PubMed ID: 10364651
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.